Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trappsol Cyclo in Adult NPC-1
NCT02939547Phase 1Completed
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Oct 2017
- Primary completion
- Feb 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Trappsol Cyclo in Niemann-Pick disease type C (NPC) (2 arms), sponsored by Cyclo Therapeutics, Inc. Primary endpoints: Maximum Concentration of Trappsol in plasma at 20 hours, Time to Maximum Concentration of Trappsol in plasma at 20 hours and 2 more. Started Oct 2017; status: completed.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT02939547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939547.